15th week of 2010 patent applcation highlights part 38 |
Patent application number | Title | Published |
20100092497 | METHODS OF IMMUNE OR HAEMATOLOGICAL ENHANCEMENT, INHIBITING TUMOUR FORMATION OR GROWTH, AND TREATING OR PREVENTING CANCER - Use of lactoferrin or metal ion lactoferrin, preferably iron lactoferrin, preferably bovine lactoferrin, preferably iron bovine lactoferrin, or a metal ion functional variant or functional fragment thereof and at least one anti-tumour food factor selected from soy protein and vitamin D inhibits tumour formation or growth, maintains or improves one or both of the white blood cell count and red blood cell count, stimulates the immune system, and/or treats or prevents cancer. Dietary (foods or food supplements), nutraceutical or pharmaceutical compositions may be used. | 2010-04-15 |
20100092498 | Anti-Tumour Vaccine Derived from Normal Chemically Modified Cells - A composition for inducing an immune response in a mammal, comprises lymphoid cells in which expression of tumor antigens has been chemically induced. The tumor antigens are induced in proliferating normal lymphoid cells, especially during the log phase of proliferation. The proliferation of the normal lymphoid cells is stimulated by normal mature dendritic cells. Most conveniently, the lymphoid cells are lymphocytes, especially peripheral blood lymphocytes. The tumor antigens are typically cancer/testis antigens, which may be chemically induced by DNA demethylation. Cancer/testis antigens are expressed in a wide range of tumors, so the composition is able to raise an immune response that is effective against a wide range of tumors, despite the fact that it is derived from normal cells. The composition may be used for preparation of an anti-tumor vaccine for prophylactic or therapeutic use. The composition may also be used for ex vivo activation of cytotoxic T lymphocytes, followed by expansion of the cytotoxic T lymphocyte population by normal dendritic cells, for cancer treatment by adoptive T cell immunotherapy. | 2010-04-15 |
20100092499 | Alpha Thymosin Peptides as Cancer Vaccine Adjuvants - A pharmaceutical combination and method for enhancing cancer vaccine effectiveness in a subject, utilize an immune response-triggering cancer vaccine capable of eliciting an immune system response in a subject; and a vaccine effectiveness-enhancing amount of an alpha thymosin peptide, which enhances the immune system response in the subject, wherein the cancer vaccine and the alpha thymosin peptide can be administered separately or together. | 2010-04-15 |
20100092500 | NOVEL IMMUNOGENIC LIPOPEPTIDES COMPRISING T-HELPER AND B-CELL EPITOPES - The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and B cell epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular antigens. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the B cell epitope or within the T-helper epitope. | 2010-04-15 |
20100092501 | FOXP3 PEPTIDE VACCINE - The present invention provides Foxp3 peptides comprising the amino acid sequence of SEQ ID NOs: 3-5, 7-9, 12, 15-19, 22, 24, 27-30, 37, 67 or 74, and Foxp3 peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for regulating regulatory T cells comprising these Foxp3 peptides. The Foxp3 peptides of this invention find use as vaccines. | 2010-04-15 |
20100092502 | MODIFIED HIV ENV POLYPEPTIDES - Polynucleotide encoding modified HIV Env polypeptides are disclosed. The Env polypeptides are modified so as to expose at least part of the CD4 binding region. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided. | 2010-04-15 |
20100092503 | HCV FUSION POLYPEPTIDEDS - The invention provides HCV fusion polypeptides including truncated or full-length HCV NS5 polypeptides, and a portion of the HCV NS2 polypeptide, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize against HCV. | 2010-04-15 |
20100092504 | COMBINED HUMAN PAPILLOMAVIRUS VLP/GENE DELIVERY SYSTEM AND USE THEREOF AS A VACCINE FOR PROPHYLAXIS AND IMMUNOTHERAPY OF INFECTIOUS DISEASES AND TUMORS - The present invention relates to compositions that contain a chimeric papillomavirus virus-like particle (VLP) in combination with a DNA molecule encoding a protein or polypeptide epitope. The chimeric papillomavirus VLP is assembled from an L1 protein or polypeptide and a chimeric protein or polypeptide containing at least a portion of the L2 protein and a protein or polypeptide including an immunogenic epitope. The composition is useful for inducing an enhanced immune response against a pathogen or a tumor. | 2010-04-15 |
20100092505 | Method for Shielding Functional Sites or Epitopes on Proteins - Methods of site-specifically shielding one or more binding sites within a polypeptide are disclosed, comprising attaching at least one small molecular weight, water-soluble polymer to said polypeptide such that the binding site is masked by said polymer. The shielding of a binding site (e.g., epitope) as per the disclosed methods acts to either eliminate or substantially reduce the biological response induced by the interaction between said binding site and its cognate receptor, helping to refocus the biological response toward unmasked portions of the polypeptide. Pharmaceutical products generated as per the methods described herein (e.g., polymer-modified antigens and vaccine compositions comprising them), as well as the use thereof, induce a specific immune response against unmasked portions of the polypeptides when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, generating selective immunoprotection in said mammal. | 2010-04-15 |
20100092506 | USE OF PHAEODACTYLUM ALGAE EXTRACT FOR DEPIGMENTING THE SKIN - The invention relates to the use in a cosmetic composition of an extract of the alga | 2010-04-15 |
20100092507 | PURIFIED COMPONENT OF BLUE-GREEN ALGAE AND METHOD OF USE - Disclosed herein are extracts of blue green algae, such as | 2010-04-15 |
20100092508 | Molecular Antigen Arrays - The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses. | 2010-04-15 |
20100092509 | Hypo- and Hyper- Acetylated Meningococcal Capsular Saccharides - Capsular saccharides derived from serogroups W135 and Y of | 2010-04-15 |
20100092510 | TURKEY HERPESVIRUS VECTORED RECOMBINANT CONTAINING AVIAN INFLUENZA GENES - The present invention provides a recombinant turkey herpesvirus modified by the presence of the cDNA encoding the hemagglutinin protein of avian influenza virus under a promoter. A poultry vaccine comprising the recombinant turkey herpesvirus described in the present invention can induce serological responses that may be easily detected by the hemagglutination inhibition assay but not by commercially available diagnostic ELISA kits; thus enabling easy differentiation between vaccination and field infection. | 2010-04-15 |
20100092511 | ESCHERICHIA COLI MUTANTS AND METHODS OF USE THEREOF - The present invention provides methods and compositions for production of gram-negative bacterial mutants that are defective in intestinal colonization capacity and sensitive to infection by bacteriophage P1. Thus the present invention provides immunogenic compositions for the prevention or attenuation of food- and water-borne illnesses associated with ingestion of bacteria such as enterohemorrhagic | 2010-04-15 |
20100092512 | Methods for preventing and ameiliorating porcine respiratory and reproductive syndrome virus-associated disease by immunizing against porcine ttv infection - Compositions and methods for preventing and ameliorating Porcine respiratory and reproductive syndrome virus (PRRSV)-associated diseases in pigs by immunizing against Torque teno virus (TTV) are disclosed. Also described are methods of identifying compounds for the treatment and prevention of PRRSV-associated diseases. | 2010-04-15 |
20100092513 | Methods and compositions for inducing an immune response to HIV and models for testing - The invention provides methods and compositions for raising an immune response in a subject by administering an HIV antigen. The HIV antigens include HIV clade C polynucleotides and polypeptides. The invention also provides for recombinant HIV viral particles and compositions. | 2010-04-15 |
20100092514 | METHOD AND DEVICE FOR PRODUCING VACCINE - A method of making a vaccine using animal derived component free (ADCF) cell culture technology, including the steps of attaching ADCF-adapted cells to a microcarrier including an attachment mechanism for attaching filipodia of the cells, the microcarrier being in a culture, growing the cells in ADCF maintenance media, infecting the cells with vaccine media, producing virus within the cells, and harvesting the virus. A vaccine produced by the above method in a pharmaceutically acceptable carrier. A vaccine production structure of ADCF-adapted cells removably attached to microcarrier beads including an attachment mechanism for attaching filipodia of the cells. | 2010-04-15 |
20100092515 | HERPES SIMPLEX VIRUSES AND METHODS OF VIRAL REPLICATION - A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide. | 2010-04-15 |
20100092516 | BACTERIAL GHOST (BG) PRODUCTION PROCESS USING BETAPROPIOLACTONE (BPL) FOR FINAL INACTIVATION - The invention relates to bacterial ghost preparation using betapropiolactone for final inactivation of bacteria. | 2010-04-15 |
20100092517 | Dose and localization of botulinum toxins in skin and muscle - A novel dosing regimen for the administration of botulinum toxin based on the pattern, quantity, and location of neuromuscular junctions in the target tissue. Because the number of neuromuscular junctions in a target tissue remains generally stable throughout life and because the pharmacological effect of botulinum toxin is localized at the neuromuscular junction, dosing efficacy is unaffected by muscle mass, age of the patient, or body weight. | 2010-04-15 |
20100092518 | Recombinant Intracellular Pathogen Immunogenic Compositions and Methods of Use - Immunogenic compositions comprising recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to attenuated recombinant Mycobacteria expressing the major extracellular non-fusion proteins of Mycobacteria and/or other intracellular pathogens. Other embodiments are provided wherein the recombinant attenuated intracellular pathogen is auxotrophic. | 2010-04-15 |
20100092519 | COMPOSITIONS COMPRISING POLYSACCHARIDE CONJUGATES AND THEIR USE AS VACCINES - The present invention is in the field of combination therapies, including vaccine compositions, which comprise polysaccharide-protein conjugates and outer membrane vesicles (OMVs) from commensal bacteria, particularly commensal | 2010-04-15 |
20100092520 | Recombinant Plasmodium Falciparum Merozoite Surface Proteins 4 and 5 and Their Use - Accordingly, the invention provides constructs in which the nucleic acids encoding | 2010-04-15 |
20100092521 | ANTIGENICITY OF INFECTIOUS PANCREATIC NECROSIS VIRUS VP2 SUB-VIRAL PARTICLES EXPRESSED IN YEAST - Infectious pancreatic necrosis virus (IPNV), the etiologic agent of infectious pancreatic necrosis in salmonid fish, causes significant losses to the aquaculture industry. The gene for the viral capsid protein (VP2) was cloned into a yeast expression vector and expressed in | 2010-04-15 |
20100092522 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF - This invention provides peptides, immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same. | 2010-04-15 |
20100092523 | MOLECULES AND METHODS FOR TREATMENT AND DETECTION OF CANCER - The invention provides a method for inhibiting proliferation of cancer cells, as well as methods for detecting and treating various cancers, including cancer of the ovary, breast, prostate and colon. The method comprises contacting a cancer cell with an IGF-related molecule of the invention or administering an IGF-related vaccine to the cancer patient. In one embodiment, the molecule is an immunogenic peptide derived from IGFBP-2 or from IGF1 R. The invention additionally provides methods for detecting and treating cancer using IGF-related molecules. | 2010-04-15 |
20100092524 | MODIFICATION OF EXOSOMAL COMPONENTS FOR USE AS A VACCINE - The presently disclosed subject matter provides modified cell-derived exosomes substantially lacking one or more immunosuppressive polypeptides. The presently-disclosed subject matter further provides methods of producing the modified exosomes and methods of using the modified exosomes for treating cancers. | 2010-04-15 |
20100092525 | MEDICAL DEVICE - A medical device for delivery of a therapeutic agent to a physiological target site includes a flexible receptacle containing said therapeutic agent, wherein at least a part of the receptacle is formed of a water-soluble or water-dispersible material. The therapeutic agent may include a haemostatic agent and the physiological target site may be a wound. | 2010-04-15 |
20100092526 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME - The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a | 2010-04-15 |
20100092527 | GLASS FLAKES, AND COSMETIC CONTAINING THE SAME - The glass flakes of the present invention each include a glass flake substrate and a coating layer coating the surface of the glass flake substrate. The glass flake substrates have an average thickness of 0.1 to 1.0 μm, and an average particle size of 1 to 100 μm. The coating layers are formed of methyl hydrogen silicone and the content percentage of the coating layers is 0.05 to 2.50 mass % as determined by ignition loss at 625±20° C. | 2010-04-15 |
20100092528 | FRUCTAN-BASED EPILATORY COMPOSITIONS - The invention relates to an epilatory mixture comprising a fructan, preferably inulin. Furthermore, an epilatory composition is disclosed comprising said epilatory effective mixture. Also a method of use of said epilatory composition of the invention for the removal of unwanted hair from the skin is disclosed, as well as a method of use of said composition for carrying out an epilatory treatment which can be carried out by a professional person as well as by a non-professional person. | 2010-04-15 |
20100092529 | Method for Acaricidal and Microbicidal Treatment of Textile Materials - The present invention concerns a method of agaricidal and microbicidal treatment of textile materials, a Neem oil microcapsule composition specifically for said treatment and a bioactive textile material obtained. More particularly, the present invention concerns the industrial and commercial areas of the treatment of fabrics and like products and is of particular application to textile materials produced from natural fibers such as cotton, feathers or down, or synthetic fibers such as polyester, nylon, acrylic or the like, or mixed fibers such as polyester-cotton. The present invention concerns a method of agaricidal and microbicidal treatment of a textile material, in which microcapsules containing Neem oil are fixed on said textile material. | 2010-04-15 |
20100092530 | Novel Triclosan Salts - Novel silver-triclosan salts are provided which have antimicrobial properties and may be used as pharmaceutical compositions or to treat articles such as medical devices, packaging materials, and textiles. | 2010-04-15 |
20100092531 | TEXTILE IMPLANT OF SHEATH-CORE CONSTRUCTION AND METHOD OF FORMING IT - A textile implant includes at least one thread having a polymeric core and a polymeric sheath which surrounds the polymeric core at least partly, wherein the sheath includes a composition including at least one silica-supported antimicrobial active agent. | 2010-04-15 |
20100092532 | Materials and Methods for Treating and Managing Angiogenesis-Mediated Diseases - Disclosed herein are materials and methods suitable for treating sites of pathological angiogenesis and abnormal neovascularization. Sites of pathological angiogenesis or abnormal neovascularization can be treated by contacting a surface at or adjacent or in the vicinity of an area of pathological angiogenesis or abnormal neovascularization with an implantable material. The implantable material comprises a biocompatible matrix and cells and is in an amount effective to treat the affected site. The composition can be a flexible planar material or a flowable composition. Diseases susceptible to treatment with the present invention include, for example, macular degeneration, rheumatoid arthritis, psoriasis, psoriatic arthritis, systemic inflammatory diseases, and treatment of tumors by surgical resection, radiation therapy or chemotherapy. | 2010-04-15 |
20100092533 | Bioabsorbable Surgical Composition - Bioabsorbable macromer compositions are provided including a polymeric component possessing a hydroxamate segment and a polymer segment. The polymeric component can be used by itself, or in some embodiments, combined with a second component, to form a macromer composition of the present disclosure. The resulting bioabsorbable macromer composition can be employed as an adhesive or sealant for medical/surgical uses. | 2010-04-15 |
20100092534 | Combination Local Delivery Using a Stent - Described herein are implantable medical devices useful in treating vascular conditions such as restenosis. In one embodiment, stents are described in which a combination of bioactive agents is described for local delivery in the vasculature. The combination of bioactive agents comprises at least one compound capable of inhibiting smooth muscle cell proliferation and at least one compound capable of mitigating MCP- and/or TF induction. For example, a compound capable of inhibiting smooth muscle cell proliferation is a mTOR inhibitor and a compound capable of mitigating MCP-1 and/or TF induction is a corticosteroid. | 2010-04-15 |
20100092535 | Nanoporous Drug Delivery System - Disclosed herein are controlled release drug delivery systems. The systems comprise a medical device at least one nonoporous surface, at least one bioactive agent and optionally a biodegradable polymer. The nanoporous surfaces of the medical devices contain nanopores capable of acting as reservoirs for drugs that are controllably released. | 2010-04-15 |
20100092536 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS - Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal. | 2010-04-15 |
20100092537 | SURGICAL IMPLANT COMPOSITE MATERIALS AND KITS AND METHODS OF MANUFACTURE - A surgical implant composite material comprises a surgical implant substrate and a thin film coating deposited on the substrate, the thin film coating comprising TiO | 2010-04-15 |
20100092538 | Nucleic Acids Encoding Spider Glue Proteins and Methods of Use Thereof - Nucleic acids encoding spider glue proteins and methods of use thereof are disclosed. | 2010-04-15 |
20100092539 | Fluorinated GHRH Antagonists - Novel fluorinated synthetic analogs of hGH-RH(1-30)NH | 2010-04-15 |
20100092540 | DRUG DELIVERY COMPOSITIONS AND MEDICAL DEVICES CONTAINING BLOCK COPOLYMER - A composition for delivery of a therapeutic agent is provided. The composition comprises: (a) a biocompatible block copolymer comprising one or more elastomeric blocks and one or more thermoplastic blocks and (b) a therapeutic agent, wherein the block copolymer is loaded with the therapeutic agent. The block copolymer is preferably of the formula X-(AB) | 2010-04-15 |
20100092541 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 2010-04-15 |
20100092542 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 2010-04-15 |
20100092543 | Dimpled adhering troche for use on teeth or orthodontic braces - A dissolving oral adhering disc with a dimple on at least one side to improve adhesion to hard convex surfaces in the mouth, including teeth, orthodontic braces, and gums (keratinized gingiva). The disc may be designed to prevent or treat a sore in the mouth opposite a tooth or brace and/or to release a medication into the mouth, to treat such as sore or to treat or prevent conditions elsewhere in the mouth or throat or stomach with the medication may be a form a glycyrrhetinic acid that is soluble in water at human mouth temperatures. | 2010-04-15 |
20100092544 | Adhesive composition for patch and use thereof - The present invention provides an adhesive composition for patch, containing a rubber elastomer and a tackifier having a weight average molecular weight of 1200-2500, a patch having a support and an adhesive layer containing the composition, which is provided on at least one surface of the support, and a patch preparation having an adhesive layer containing a percutaneously absorbable drug (excluding bisoprolol). | 2010-04-15 |
20100092545 | POLYETHYLENE-OXIDE BASED FILMS AND DRUG DELIVERY SYSTEMS MADE THEREFROM - The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film. | 2010-04-15 |
20100092546 | Topical and Transdermal Delivery of HIF-1 Modulators to Prevent and Treat Chronic Wounds - Compositions and methods are provided for the treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound. Agents that increase HIF-1α activity include, without limitation, agents that stabilize HIF-1α, e.g. deferoxamine, deferiprone, deferasirox, etc.; agents that upregulate expression of HIF-1α, e.g. dimethyloxalylglycine, etc., HIF-1α polypeptide or coding sequences; and combinations thereof. Such agents may be referred to herein as HIF-1α potentiating agents. | 2010-04-15 |
20100092547 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS - A method for prophylaxis and/or treatment of mucositis comprising the steps of providing a therapeutically effective amount of a composition comprising either (1) at least one compound selected from the group consisting of 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; or (2) a cytokinin compound; and administering the composition to a subject in need of such treatment. Also provided are pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione and/or a cytokinin compound and use of these compositions in the preparation of a medicament for the treatment and/or prophylaxis of mucositis. The cytokinin compound may be selected from, but is not limited to N | 2010-04-15 |
20100092548 | CHEWABLE SOFTGEL CAPSULES - A chewable softgel capsule configured for encasing orally ingestible articles. The chewable soft capsule is provided with an outer shell composition which comprises at least one gelatin in a range of 20% to 60% of the total weight of the shell composition, at least one plasticizer in an amount selected to render flexible the outer shell composition, an anti-tacking agent in an amount selected to render the outer shell composition non-sticky, and water. In one embodiment the chewable soft capsule further comprises at least one starch in a range of 0.1% to 35% of the total weight of the shell composition. The chewable softgel capsule is suitable for encasing therein medicines, pharmaceutical compositions, nutraceuticals, vitamins, nutritional supplements, and the like. | 2010-04-15 |
20100092549 | Dosage Form Containing Two or More Active Pharmaceutical Ingredients in Different Physical Forms - A dosage form for administration of two or more active pharmaceutical ingredients to a subject, comprising a first pharmaceutical composition comprising a first active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a first physical form selected from the group consisting of powder, granule, pellet, bead or mini-tablet form, and at least a second pharmaceutical composition comprising a second active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a second physical form selected from the group consisting of granule, pellet, bead, mini-tablet or tablet form, wherein the composition is characterised in that said first and second physical forms are selected to be different to minimise interactions between said first and second pharmaceutical compositions and to allow separation of said first and second pharmaceutical compositions for analysis on the basis of size difference. | 2010-04-15 |
20100092550 | ALKA-EEZE - A composition for providing relief from acidity. The composition comprises sodium bicarbonate for use in neutralizing acids. There is one of a capsule and a tablet for enclosing the sodium bicarbonate therein, such one of such capsule and such tablet being a delayed release and a timed release system so as to delay the dissolution of the sodium bicarbonate until the sodium bicarbonate is in one of a small intestine and a large intestine. | 2010-04-15 |
20100092551 | SOLID PREPARATION COMPRISING ALOGLIPTIN AND PIOGLITAZONE - A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which is useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts:
| 2010-04-15 |
20100092552 | LOW DOSE CONTROLLED RELEASE TABLET - Low dose pharmaceuticals can be delivered for a prolonged period using a tablet-in-tablet design wherein the drug is contained in a controlled release matrix in the outer compression coating layer but not in the inner tablet core. | 2010-04-15 |
20100092553 | ANTI-MISUSE MICROPARTICULATE ORAL PHARMACEUTICAL FORM - The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. | 2010-04-15 |
20100092554 | COMBINATION WITH AN EXTENDED RELEASE TABLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention is directed to a combination of an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof with a conventional treatment option of Parkinson's Disease. | 2010-04-15 |
20100092555 | SOFT TABLET CONTAINING HIGH MOLECULAR WEIGHT CELLULOSICS - The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient having an optional tastemasking coating, and a matrix comprising hydroxyalkylcellulose having a weight average molecular weight of from about 60,000 to about 5,000,000. The tablet possesses exceptionally good mouthfeel and stability. | 2010-04-15 |
20100092556 | ALFUZOSIN FORMULATIONS, METHODS OF MAKING, AND METHODS OF USE - Alfuzosin compositions comprising a tablet core of alfuzosin and a release-retarding matrix comprising about 40 to about 80% (by weight) hydroxypropyl methyl cellulose with a maximum apparent viscosity of about 5600 cP, based on the total weight of the tablet core; and an extended-release coating substantially surrounding the tablet core comprising a release-retarding coating material, wherein the compositions are bioequivalent to the reference dosage form of NDA #021287 (UROXATRAL) are disclosed. Methods of making and using the alfuzosin compositions are also disclosed. | 2010-04-15 |
20100092558 | Method for Producing a Product Having a Polymer Matrix, Implants Made Thereof and Use Thereof - The invention concerns a method for the production of a product having a polymer matrix, products which can be produced in accordance therewith and the use thereof. | 2010-04-15 |
20100092559 | BOLDINE COMPOUNDS FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer. | 2010-04-15 |
20100092560 | REDUCED COENZYME Q10-CONTAINING PARTICULATE COMPOSITION AND METHOD FOR PRODUCING THE SAME - The present invention aims to propose a particulate composition containing reduced coenzyme Q10, which simultaneously shows high oxidative stability and high absorbability in the body and a production method thereof, as well as a stabilizing method thereof, to be used in the fields of foods, foods with nutrient function claims, foods for specified health uses, nutritional supplements, nutritional products, animal drugs, beverages, feeds, cosmetics, pharmaceuticals, therapeutic drugs, prophylactic drugs and the like. The present inventors have conducted intensive studies in an attempt to solve the aforementioned problems and found that a particulate composition containing reduced coenzyme Q10, wherein an oil component containing the reduced coenzyme Q10 is polydispersed forming a domain in a matrix containing a water-soluble excipient as a main component and a water-soluble ascorbic acid is a composition simultaneously having high oxidative stability and high absorbability in the body, and completed the present invention. | 2010-04-15 |
20100092561 | METHODS AND COMPOSITIONS USING SUBSTANCE P TO PROMOTE WOUND HEALING - Healing of wounds in mammalian tissue may be enhanced by the application of certain neuropeptides, optionally in combination with known growth promoting hormones. Exemplary neuropeptides include tachykinins, such as Substance P, Substance K, and the like, as well as calcitonin gene-related peptides. The compositions may further include a polymeric delivery carrier and are utilized by applying to the site of the wound. Wounds may be vascular or avascular wounds. The compositions promote elaboration of cellular matrices and development of cellular attachment mechanisms in addition to stimulating cellular proliferation. | 2010-04-15 |
20100092562 | SUSTAINED-RELEASE DRUG DELIVERY COMPOSITIONS AND METHODS - The present invention relates to liquid sustained release suspension dosage forms. In particular, the invention encompasses sustained release compositions comprising a dispersed phase, which contains an ion-exchange matrix drug complex, a diffusion controlling membrane coating and a dispersion medium comprising an excipient capable of impeding water activity such that drug dissolution is inhibited prior to administration. Further, the invention provides for compositions wherein several active ingredients associate in a single bead in the dispersed phase, such that the abuse potential of such active ingredients is reduced. The invention also encompasses sustained release formulations of combination drugs comprising an extended release phase and an immediate release phase. The formulations of the invention may be used to treat a variety of conditions and symptoms, including those that require administration of several drugs, such as cold and allergy symptoms. In one of the embodiments, the sustained release composition combines an antihistamine, an antitussive and a decongestant. The invention further provides for methods of making and using such formulations. | 2010-04-15 |
20100092563 | Methods for the Preparation of Biologically Active Compounds in Nanoparticulate Form - A method for producing a composition comprising nanoparticles of a biologically active compound. | 2010-04-15 |
20100092564 | Composition of and Method for Preparing Orally Disintegrating Tablets - An improved orally dissolving tablet (ODT) and method of manufacture is provided. The improved ODT disclosed herein are prepared by direct compression of a mixture of pharmaceutical excipients including at least one water-insoluble hydrophobic inorganic salt in combination with at least one water-insoluble inorganic salt with less hydrophobicity compared to the water-insoluble hydrophobic inorganic salt component. These components may be formed into granules, and may include other commonly used excipients. In an illustrative embodiment, the granules are formed into tablets by direct compression, optionally using a lubricant. The fast disintegrating tablets prepared using these components exhibit desirable performance properties such as sufficient hardness, low friability, quick disintegration time and good mouth-feel when compared to conventional ODT. A further advantage is that the improved ODT may be manufactured using commonly available manufacturing equipment for granulation, blending and tableting. | 2010-04-15 |
20100092565 | PHARMACEUTICAL COMPOSITION COMPRISING MICROPARTICLE OILY SUSPENSION - A pharmaceutical composition comprising a suspension of medicinally-active ingredient microparticles having a mean particle diameter of 20 μm or smaller in a base oil which can achieve extremely high intestinal absorption and bioavailability especially when the medicinally-active ingredient is hardly water-soluble. | 2010-04-15 |
20100092566 | Highly concentrated drug particles, formulations, suspensions and uses thereof - Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability. | 2010-04-15 |
20100092567 | IMMUNOSTIMULATORY NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - Provided herein are immunostimulatory nanolipoprotein particles and related compositions methods and systems. | 2010-04-15 |
20100092568 | DRUG MICROPARTICLES - Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them. | 2010-04-15 |
20100092569 | PRODUCT BASED ON CONJUGATED LINOLEIC ACID AND A METHOD FOR THE MANUFACTURE THEREOF - A product based on conjugated linoleic acid (CLA) comprises an inner core in which the conjugated linoleic acid is substantially concentrated as well as a coating for covering and protecting the inner core; the coating in turn comprises a fraction greater than 80% by weight relative to the coating of a lipid matrix formed by glycerides of C16, C18, C20 and C22 saturated fatty acids. | 2010-04-15 |
20100092570 | CONTROLLED RELEASE OXYCODONE COMPOSITIONS - A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed. | 2010-04-15 |
20100092571 | MICROCAPSULES HAVING MULTIPLE SHELLS AND METHOD FOR THE PREPARATION THEREOF - Single-core and multi-core microcapsules are provided, having multiple shells, at least one of which is formed of a complex coacervate of two components of shell materials. The complex coacervate may be the same or different for each shell. Also provided are methods for making the microcapsules. | 2010-04-15 |
20100092572 | CHITOSAN-BASED COLLOIDAL PARTICLES FOR RNA DELIVERY - The present invention provides new colloidal particles of negative zeta potential comprising a ribonucleic acid, a chitosan and a polyanion, and compositions comprising such particles. The compositions are useful for delivery of ribonucleic acids into mammalian cells in vitro, ex vivo and in vivo. | 2010-04-15 |
20100092573 | HEMOSTATIC BIO-MATERIAL COMPOSITION AND METHOD - The present invention relates to a haemostatic bio-material composition and method for achieving hemostasis. The method for providing hemostasis generally comprises: supplying a dry potassium phosphate based hemostat mixture comprising: monobasic potassium phosphate, a metal oxide, and a tertiary calcium phosphate, wherein the weight percent ratio of monobasic potassium phosphate to metal oxide is between about 3:1 and 1:1; mixing the dry potassium phosphate based hemostat mixture with an aqueous solution forming an activated hemostat slurry; applying an hemostasis-promoting amount of the activated potassium phosphate based hemostat slurry to a site of bleeding; wherein the site of bleeding is in, on, or proximate to bone. | 2010-04-15 |
20100092574 | SYNERGISTIC PEROXIDE BASED BIOCIDAL COMPOSITIONS - Disclosed is a method for controlling microbial growth in an aqueous system containing sulfite and/or bisulfite residues by addition of a peroxy compound at a pH of greater than 5. Also disclosed is a method for stabilizing an active halogen biocide in an aqueous system containing peroxide residues by addition of an N-hydrogen compound to the active halogen biocide before combining it with the peroxide containing aqueous system. Further disclosed is an optimized papermaking biocide program consisting of initially treating sulfite bleached pulp with peroxide followed by application of an N-hydrogen-stabilized active halogen compound to the paper producing white waters and an analytical method for determining peroxide concentrations in aqueous systems in the presence of sulfite and/or bisulfite. | 2010-04-15 |
20100092575 | Method of making treatment materials and using same to treat algae and/or pests - The present invention is directed to a composition for treating algae and pests in water or soil. The compositions of the present invention include an oxidizing agent, a thickener, and water. It is preferable to further include a stabilizer for the oxidizing agent. The components of the composition are preferably biocompatible with the water or soil, and more preferably biodegradable. | 2010-04-15 |
20100092576 | PHARMACEUTICAL COMPOSITIONS CONTAINING LANTHANUM HYDROXYCARBONATE - An assay for analytically determining the amount of an impurity in a solid sample is provided. This X-ray diffraction method preferably uses the Rietveld refinement. | 2010-04-15 |
20100092577 | TOPICAL COMPOSITIONS CONTAINING MAGALDRATE - Disclosed are topical compositions containing the active ingredient magaldrate mixed with suitable vehicles and excipients. | 2010-04-15 |
20100092578 | PROTEIN KINASE C IOTA - The invention involves PKC | 2010-04-15 |
20100092579 | MEDICAMENT FOR TREATING LUNG CANCER - Lung cancer can be treated effectively by combination of amrubicin or a pharmaceutically acceptable salt thereof with cisplatin. | 2010-04-15 |
20100092580 | Weight Reducing Composition - The invention relates to soft drink industry, in particular, to dietetic nutrition. The inventive weight reducing composition comprises 0.01-10 mg/l of sodium and 25-150 mg/l of magnesium, the rest being water. Said composition (drinking water) makes it possible to reduce weight without altering the usual eating habits. In addition, consumption of said drinking water results in reduction of weight by 1.2-2.9 kg. | 2010-04-15 |
20100092581 | ANTIBACTERIAL COMPOSITIONS COMPRISING AN EXTRACT FROM ARCEUTHOBIUM - This application relates to an antibacterial composition comprising an extract from a plant belonging to the genus | 2010-04-15 |
20100092582 | Topical Hair Care Formulation and Method of Making - A topical hair care formulation and method of making includes combining generally equal amounts of eclipta alba herbal powder and embelica officinalis herbal powder to form a herbal powder mixture. The herbal powder mixture is steeped in an amount of base oil for a period of time to form a brown solution. A portion of an amount of olive oil is combined with an amount of biotin and an amount of Methylsulfonylmethane to form a natural mixture. A remainder of the amount of olive oil is combined with the brown solution. An amount of jojoba oil is combined with the brown solution. An amount of rosemary oil is combined with the brown solution. An amount of lavender oil is combined with the brown solution. The natural mixture is combined with the brown solution. The brown solution is settled for a period of time to form the topical hair care formulation. | 2010-04-15 |
20100092583 | Antioxidant-Enriched Fruit Extracts and Uses Thereof in the Treatment and Prevention of Diabetes and Obesity - A method of treating or preventing diabetes or obesity that comprises administering an antioxidant-enriched composition produced by fermenting fruit extracts with the bacteria | 2010-04-15 |
20100092584 | Composition Comprising the Extract of Combined Herbs for Preventing and Treating Liver Disease - The present invention is related to a combined herb composition comprising herbs of | 2010-04-15 |
20100092585 | PLANT EXTRACTION METHOD AND COMPOSITIONS - The present invention pertains to methods of extracting cardiac glycosides from cardiac glycoside containing plant material, such as | 2010-04-15 |
20100092586 | Natural water soluble extracts for the inhibition of alpha-1-adrenergic receptors - The present invention discloses therapeutic natural products, in particular plant extracts effective in treating and preventing urinary tract disorders, and method for obtaining said extracts. In particular, the present invention discloses a water-soluble alcoholic extract of | 2010-04-15 |
20100092587 | MOLD FIXING SYSTEM - Each of a plurality of injection molding machines is provided with clamp plates fixed on platens and a plurality of magnet units to generate magnetic force for fixing a mold to the clamp plate fitted on the clamp plates; and the plurality of injection molding machines are provided with a plurality of common connectors having the same structure, each of which is electrically connected to the magnetic unit, a molding machine control unit and a power source device; and the mold fixing system comprises a set of operation control units to be shared by the plurality of injection molding machines, and when a mold is to be exchanged in any of the injection molding machines, the plurality of magnet units are switched to the non-adsorbing state or the adsorbing state via the operation control unit in the state where the operation control unit is connected to the common connector of the injection molding machine. | 2010-04-15 |
20100092588 | Injection Molding Apparatus Having Magnetic Valve Pin Coupling and Related Method - An actuated part, such as a valve pin plate or actuator piston, is movable in forward and rearward directions. A coupling part is located rearward of the actuated part and held in position by magnetic attraction between the coupling part and the actuated part. A valve pin is coupled to the coupling part. The valve pin extends in the forward direction for opening and closing a mold gate. When a stopping force applied to the valve pin is greater than a force of the magnetic attraction between the coupling part and the actuated part, the actuated part moves away from the coupling part in the forward direction, thereby reducing the stopping force on the valve pin. | 2010-04-15 |
20100092589 | SPLICE BAR FOR TIRE TREAD EXTRUSION APPARATUS - A splice bar for a tire tread die designed for providing a narrow strip of electrically conductive rubber extending from a lower under tread to the surface of the outer tread by positioning a slotted chimney block in a the outer tread rubber passage and having a passage between the chimney slot and the under tread rubber passage specially shaped for improving the flow of rubber during extrusion. This passage is essentially straight for guiding a strip-shaped stream of rubber of the under tread to the chimney slot. The passage intersects the rear surface of the splice bar to form a generally rectangular shaped corridor extending from the rear surface to the chimney slot. | 2010-04-15 |
20100092590 | TIRE FORMING MOLD - A tire forming mold in which a depression for forming a land portion of a tread surface is provided in a molding surface forming a tread pattern of a tire. The tire forming mold has a pocket provided in the depression, a block fitted into the pocket to form an exhaust chamber in an inner portion of the pocket and holding a laminated blade, which is formed by superposing thin plates, so that one end portion is exposed to the molding surface and the other end portion is exposed to the exhaust chamber, and an exhaust hole having one end portion is communicated with the exhaust chamber and the other end portion is communicated with a mold back face or a mold split face. | 2010-04-15 |
20100092591 | PARTICLE SPREADER - The invention relates to a dispersion installation for dispersing dispersible material on a dispersing material conveyor belt so as to form groups of material for producing wood-material boards. Said system comprises at least one dispersion material bunker for the dispersible material dispersed on the dispersing material conveyor belt, having at least one top side filling opening. A chute is connected to the tilling opening via which the dispersible material can enter into the dispersion material bunker. The invention is characterised in that at least one brake cylinder device is arranged inside the chute, said brake cylinder comprising at least two rotationally driven brake cylinders. | 2010-04-15 |
20100092592 | TRANSFER BOARD - A transfer board for transferring a columnar primary compression molded product whose two bottom faces may be bulged and which is supplied continuously one by one due to its own weight since the products continue vertically in a shooter into a mortar of a secondary tablet compression machine, for example, rotary tablet compression machine, in a state where the columnar direction is substantially horizontal, having at least an inclined portion having a plane-state inclined face, an input portion adjacent thereto, a portion for limiting drop of primary compression molded product, and a bottom plate provided at a lower part of the input portion, the inclined face being inclined so as to become lower toward the input portion, the inclined portion and the adjacent input portion performing a linear motion or rotary motion at a constant speed horizontally in a direction opposite to the input portion, and the input portion and the bottom plate being able to supply the primary compression molded product into the mortar of the secondary tablet compression machine while the columnar direction is kept substantially in a state of the horizontal direction. | 2010-04-15 |
20100092593 | Blow molding device - A blow molding device capable of securely closing a lower end of a parison to prevent the parison from being crushed. The blow molding device includes a blow mold and a parison holding unit. The parison holding unit includes an inner holding plate adapted to be inserted in an interior of the lower end of the parison, and an outer holding plate adapted to hold an outer surface of the lower end of the parison, and the outer holding plate has a recess conforming to a configuration of the inner holding plate and is split into a plurality of holding plate members such that each of the split holding plate members is capable of sliding to hold the lower end of the parison. | 2010-04-15 |
20100092594 | Device for moulding parts of a plastic material - A molding device including a mold having a stationary portion arranged on a stationary platen of a press, and a movable portion arranged on a movable platen of the press, at least one injection channel for injecting material into the movable portion of the mold, and a feeder device for feeding the mold with plastics material, the feeder device including a stationary installation including a first metering device for metering a first quantity of material. The feeder device includes at least one second metering device arranged on the movable platen, the second metering device being connected to the first metering device in such a manner as to be fed with plastics material by said first metering device, and being connected to the injection channel for injecting material into the movable portion of the mold in such a manner as to be capable of feeding it with plastics material. | 2010-04-15 |
20100092595 | HOT-RUNNER NOZZLE WITH TEMPERATURE SENSOR - An injection molding hot runner nozzle ( | 2010-04-15 |
20100092596 | TABLET COMPRESSION MACHINE - A tablet compression machine which can manufacture a tablet having a plurality of layers by applying secondary compression molding to a columnar primary compression molded product formed by a plurality of layers and whose two bottom faces may be bulged, comprising at least a mortar, an upper pestle, and a lower pestle, in which the mortar is substantially in a shape in which a part of a flat plate is punched by a closed curve in a direction perpendicular to a plane of the flat plate, the upper and lower pestles are in a shape fitted with an inner face of the mortar, a space formed by an inner face of the mortar, a lower face of the upper pestle, and an upper face of the lower pestle is in a shape of an intended tablet in the secondary compression molding, a dent formed by the inner face of the mortar and the upper face of the lower pestle can constitute a shape suitable for receiving the primary compression molded product, and a direction of the secondary compression molding is different from the compression molding direction of the primary compression molded product. According to such a tablet compression machine, a multilayer tablet in a shape having a multilayer structure and not limited to columnar can be manufactured. | 2010-04-15 |
20100092597 | PROCESS AND DEVICE FOR PRODUCING BLOCKS OF MATERIAL - In a process and a device for producing blocks of expanded polystyrene, a loose mass ( | 2010-04-15 |